Johnson & Johnson JNJ earnings Q1 2021 beat estimates


Johnson & Johnson’s coronavirus disease (COVID-19) vaccines are seen at Northwell Health’s South Shore University Hospital in Bay Shore, New York, March 3, 2021.

Shannon Stapleton | Reuters

Johnson & Johnson on Tuesday reported $100 million in first-quarter sales of its Covid-19 vaccine that’s on hold in the U.S. while federal health regulators investigate a rare blood-clotting issue.

In releasing its first-quarter financial results, the company also reported earnings and revenue that beat Wall Street’s expectations.

Here’s how J&J did compared with what Wall Street expected, according to average estimates compiled by Refinitiv:

  • Adjusted EPS: $2.59 per share vs $2.34 expected.
  • Revenue: $22.32…

Source cnbc.com

IEA warns Covid recovery anything but sustainable

Previous article

Kansas City Southern, Altria, IBM & more

Next article

You may also like

Leave a Reply

Notify of

More in Earnings